Abstract:New rhodium and iridium complexes containing the bidentate ligand 3,5-diphenyl-2-(2-pyridyl)pyrrolide (PyPyr) were prepared. The bis(ethylene) complex (PyPyr)Rh(C(2)H(4))(2) (3) reacted with HSiEt(3), HSiPh(3), and HSi(t)BuPh(2) to produce the 16-electron Rh(V) bis(silyl)dihydrides (PyPyr)Rh(H)(2)(SiEt(3))(2) (8), (PyPyr)Rh(H)(2)(SiPh(3))(2) (9), and (PyPyr)Rh(H)(2)(Si(t)BuPh(2))(2) (10), respectively. The analogous Ir(V) bis(silyl)dihyride (PyPyr)Ir(H)(2)(SiPh(3))(2) (11) has also been synthesized. X-ray crys… Show more
“…They revealed that the isomer of [Rh{κ 2 -(N,N)-(C 6 F 5 )NC(Me)CHC(Me)N(C 6 F 5 )}(H)-(SiMe 3 )(CO)] (10a), which exhibits a mutual cis orientation of the hydrido and the carbonyl ligands and in which the silyl ligand occupies the apical position in a square-pyramidal complex, is the only isomer that converged to a stable structure (Figure 8; see the Supporting Information). Such a geometry with the silyl ligand in the apical position can also be found for [Rh{κ 2 -(N,N)-3,5-diphenyl-2-(2-pyridyl)-pyrrolido}(H)(SiPh 3 )(PPh 3 )] [35] and trans-[Os(SiR 3 )(Cl)-(CO)(PPh 3 ) 2 ]…”
Section: Thementioning
confidence: 54%
“…[11,31] The NMR spectroscopic data are in accordance with those found for other bis(silyl)-rhodium(V) complexes, in which the silyl ligands are in a mutual trans orientation. [35] DFT calculations were performed to model conceivable configurations of 10a and 16. They revealed that the isomer of [Rh{κ 2 -(N,N)-(C 6 F 5 )NC(Me)CHC(Me)N(C 6 F 5 )}(H)-(SiMe 3 )(CO)] (10a), which exhibits a mutual cis orientation of the hydrido and the carbonyl ligands and in which the silyl ligand occupies the apical position in a square-pyramidal complex, is the only isomer that converged to a stable structure (Figure 8; see the Supporting Information).…”
Section: Thementioning
confidence: 99%
“…There is no indication of the pres- ence of a non-classical structure (i.e., an interaction between a silyl and a hydrido ligand). [37] Note that often bis(silyl) complexes show a mutual cis orientation of the SiR 3 ligands, [36,38] but trans arrangements are also known [31,35] . [11] Such a degradation reaction can be avoided by the use of the highly fluorinated β-diketimine 17.…”
“…They revealed that the isomer of [Rh{κ 2 -(N,N)-(C 6 F 5 )NC(Me)CHC(Me)N(C 6 F 5 )}(H)-(SiMe 3 )(CO)] (10a), which exhibits a mutual cis orientation of the hydrido and the carbonyl ligands and in which the silyl ligand occupies the apical position in a square-pyramidal complex, is the only isomer that converged to a stable structure (Figure 8; see the Supporting Information). Such a geometry with the silyl ligand in the apical position can also be found for [Rh{κ 2 -(N,N)-3,5-diphenyl-2-(2-pyridyl)-pyrrolido}(H)(SiPh 3 )(PPh 3 )] [35] and trans-[Os(SiR 3 )(Cl)-(CO)(PPh 3 ) 2 ]…”
Section: Thementioning
confidence: 54%
“…[11,31] The NMR spectroscopic data are in accordance with those found for other bis(silyl)-rhodium(V) complexes, in which the silyl ligands are in a mutual trans orientation. [35] DFT calculations were performed to model conceivable configurations of 10a and 16. They revealed that the isomer of [Rh{κ 2 -(N,N)-(C 6 F 5 )NC(Me)CHC(Me)N(C 6 F 5 )}(H)-(SiMe 3 )(CO)] (10a), which exhibits a mutual cis orientation of the hydrido and the carbonyl ligands and in which the silyl ligand occupies the apical position in a square-pyramidal complex, is the only isomer that converged to a stable structure (Figure 8; see the Supporting Information).…”
Section: Thementioning
confidence: 99%
“…There is no indication of the pres- ence of a non-classical structure (i.e., an interaction between a silyl and a hydrido ligand). [37] Note that often bis(silyl) complexes show a mutual cis orientation of the SiR 3 ligands, [36,38] but trans arrangements are also known [31,35] . [11] Such a degradation reaction can be avoided by the use of the highly fluorinated β-diketimine 17.…”
“…The cycle A is completed by addition of HSi(OEt) 3 to 10 , which shows the elimination of 4 a (i.e., 11 is formed) and MeSSi(OEt) 3 . This process presumably occurs either by sigma‐bond metathesis through an η 2 ‐silane,22 for example, F , or oxidative addition to give a Rh V species 23. Intermediates, such as F , have recently been invoked in reactivity of CS bonds with silanes 13a.…”
A new functional-group tolerant, rhodium-catalyzed, sulfide-reduction process is combined with rhodium-catalyzed chelation-controlled hydroacylation reactions to give a traceless hydroacylation protocol. Aryl- and alkenyl aldehydes can be combined with both alkenes, alkynes and allenes to give traceless products in high yields. A preliminary mechanistic proposal is also presented.
“…13,14 Although there are only a few metal complexes of pyridylpyrrolide in literature, it has been shown that this ligand can stabilize high-valent, polyhydride iridium complexes. [15][16][17][18][19][20][21][22][23] The pyridylpyrrolide derivative that will be implemented in this work is the ligand 3,5-bis(trifluoromethyl)-2-(2′-pyridyl)pyrrole [(X)(L)] (X = H + or K + ). 14 The choice of the electron withdrawing trifluoromethyl groups originates from the idea of diminishing the basicity of the pyrrolide amine, thus lessening the chance of L − experiencing protonation and subsequent demetallation in the presence of acid or adventitious H + sources.…”
The synthesis and characterization of a series of iridium(I) and iridium(III) complexes supported by a 3,5-bis(trifluoromethyl)-2-(2'-pyridyl)pyrrole (L(-)) ligand are reported. Compound [Ir(L)(COD)] (COD = 1,5-cyclooctadiene) demonstrates reversible binding of hydrogen to form a dihydride complex [Ir(L)(H)(2)(COD)] with no hydrogenation of COD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.